Ernst-Gunter Afting, president of Hoechst's French pharmaceutical subsidiary Roussel Uclaf, has resigned and will leave the company on January 31, 1995.
Professor Afting is to be replaced by Jean-Pierre Godard, who currently heads up Hoechst's pharmaceutical division in Frankfurt. Mr Godard is also appointed a vice president and retains his duties at Hoechst.
Hoechst is also bringing in a change in operational structure at Roussel in order to bring it in line with the Hoechst Roussel partnership. The changes affecting human health care operational management will focus on R&D, production, marketing and sales. A joint operational committee will be set up and this will be headed by Mr Godard.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze